Intrinsiqq
Aedes S.p.A. logo

Aedes S.p.A. (AEDES.XMIL) DCF Valuation

Every assumption below is yours to change. The defaults are derived from this company's own filing history, not from a house view.

TTM free cash flow is negative (-€2M). Projecting from a negative base produces nonsense, so this model uses the average of the last three positive years (€2M) instead. Treat every figure here as a rough estimate that assumes a return to historical profitability.

Conservative

6.09

0% undervaluedvs 0.00

Growth 1–5Y%
Growth 6–10Y%
Terminal growth%
WACC%
Safety margin%

Base

8.31

0% undervaluedvs 0.00

Growth 1–5Y%
Growth 6–10Y%
Terminal growth%
WACC%
Safety margin%

Optimistic

13.35

0% undervaluedvs 0.00

Growth 1–5Y%
Growth 6–10Y%
Terminal growth%
WACC%
Safety margin%

Where today's price sits

Today 0.00
Conservative €6.09
Base €8.31
Optimistic €13.35

Today's price falls outside the modelled range.

Base free cash flow

€2M

3-year average, TTM negative

Historical FCF CAGR

+0.0%

Across 5 reported periods

Market implies

No solution in range

Terminal value share

62%

Of the base case valuation

Growth needed to justify today's price

Today's price cannot be reproduced by any growth rate between -30% and +60%, so there is no break-even curve to draw.

No growth rate in the tested range reproduces today's price at these assumptions.

Curve holds terminal growth at 2.5%, years 6 to 10 at half the first-stage rate, and applies no safety margin.

Free cash flow history

The most recent period is the base every projection starts from. Compounded, that history is +0.0% a year.

Source: company annual reportsLast synced Jun 22, 2026Base FCF €2M (3-year average, TTM negative)

A DCF output is an assumption-sensitive range, not a price target. This model is an algorithmic estimate from your inputs and company filings, and it is not a recommendation to buy, sell or hold. Terms · Methodology

Aedes S.p.A. (AEDES.XMIL) DCF: intrinsic value and margin of safety

Intrinsiqq's two-stage DCF values Aedes S.p.A. (AEDES.XMIL) at about €11.08 per share, or €8.31 with a 25% margin of safety. Every assumption is adjustable below; this is analysis, not investment advice.

Frequently asked

What is Aedes S.p.A.'s (AEDES.XMIL) fair value?+

Intrinsiqq's two-stage discounted cash flow (DCF) model estimates an intrinsic value of about €11.08 per share for AEDES.XMIL. It projects recent free cash flow forward at a growth rate that fades toward a long-run rate, then discounts those cash flows back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €8.31. The output moves with the growth and discount-rate inputs, so it is best read as a range, not a single number. You can change every assumption with the sliders on this tab.

What growth is priced into Aedes S.p.A.?+

The base case grows AEDES.XMIL's free cash flow at about 8.0% a year before fading. If the price implies growth well above what the company has actually delivered, the market is paying for optimism; if below, expectations are modest. Adjust the growth assumption on this tab to see what the current price is really betting on.

What is a good margin of safety for Aedes S.p.A.?+

A margin of safety is the discount to intrinsic value you demand before buying, to protect against being wrong on the inputs. Intrinsiqq applies 25% by default, which turns AEDES.XMIL's €11.08 intrinsic estimate into a €8.31 entry. Wider margins suit less predictable businesses; you can set your own on this tab. This is analysis from company filings, not investment advice.

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.